Emergent BioSolutions

Emergent BioSolutions

A life sciences company with a focus on biotechnology and vaccines. It was founded in 1998 and is located in Gaithersburg, Maryland.

Emergent BioSolutions is a Maryland-based biotechnology company that develops and manufactures healthcare solutions. It manufactures products, platforms, and other technologies to address public health threats. Its therapies have been used in the past for illnesses such as anthrax and botulism.

COVID-19

In 2020, Emergent BioSolutions partnered with Vaxart, a biotechnology company, to aid with developing and manufacturing Vaxart’s experimental oral vaccine candidate for COVID-19. The company is expected to produce a bulk quantity of the vaccine so that Vaxart can initiate its pre-clinical studies.

Emergent BioSolutions also partnered with Novavax, Inc. to develop and manufacture a COVID-19 vaccine candidate. According to the press release announcing the collaboration, announced in mid-March 2020, "Emergent will produce the COVID-19 experimental vaccine candidate, which is based on the proprietary recombinant protein nanoparticle technology platform of Novavax and utilizing their proprietary Matrix-M™ adjuvant to enhance immune responses. Emergent has initiated work for this program anticipating that the COVID-19 experimental vaccine candidate will be used in a Phase 1 clinical study within the next four months."

Emergent BioSolutions has partnered with the US government to expedite the development of a plasma-derived therapy, COVID-Human Immune Globulin (COVID-HIG) for severe hospitalized and high-risk patients to prevent progression to severe symptoms. The company received $14.5 million form BARDA in support of the program. COVID-HIG is a candidate human hyperimmune product, polyclonal antibody therapeutics, that will be manufactured using plasma donated from people who recovered from COVID-19 and have antibodies to SARS-CoV-2.

Timeline

Products

Product
Description
Industry
Launch date
Website

The Reactive Skin Decontamination Lotion (RSDL) Kit is an FDA-cleared device consisting of a lotion impregnated sponge in an easy-to-open packet. The RSDL Kit is intended to remove or neutralize chemical warfare agents and T-2 Toxin from the skin.

2017
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Bob Kramer

CEO

Further reading

Title
Author
Link
Type
Date

Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease | Emergent BioSolutions Inc.

Emergent BioSolutions

Web

March 10, 2020

Emergent Biosolutions, Inc. (NYSE:EBS), Novavax, Inc. (NASDAQ:NVAX) - Emergent BioSolutions CEO Talks ...

Jayson Derrick

Web

March 12, 2020

Vaxart Announces It Entered Into An Agreement With Emergent Biosolutions For The Development And Manufacturing Of Oral Coronavirus (Covid-19) Vaccine Candidate

BioSpace

Web

March 18, 2020

Documentaries, videos and podcasts

Title
Date
Link

Emergent BioSolutions, Eyeing Two Plasma Therapies for Covid-19, Wins Fed's Help

April 5, 2020

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 27, 2020
BioSpace
Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace
Darrell Etherington
April 3, 2020
TechCrunch
Last week, we spoke to the head of Emergent BioSolutions' Therapeutics Business Unit Dr. Laura Saward about her company's work developing plasma-based potential treatments for COVID-19. Now, the company announced that it has received $14.5 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.